FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma

• Status: Withdrawn
• Trial end date: 2009-03-01

Summary

This pilot study will evaluate the safety and effectiveness of chemo-radiotherapy comprising a regimen of FOLFOX6 chemotherapy plus SIR-Spheres yttrium-90 microspheres (chemo-radiotherapy, also known as "chemo-SIRT"), in combination with the biologic therapy Bevacizumab (Avastin), for the first-line treatment of patients with liver metastases from colorectal carcinoma in whom surgical resection is not feasible.

• Phase: Phase 2/Phase 3

Details

• Lead Sponsor: Sirtex Medical
• Treatments: Bevacizumab; Fluorouracil; Folic Acid; Leucovorin; Levoleucovorin; Oxaliplatin